CURE’s mantle cell lymphoma (MCL) page features the latest cancer news and updates on mantle cell lymphoma Through articles, videos, podcasts, and more, CURE brings readers the insights of experts, cancer survivors, patients, and advocates to ensure everyone is up to date in mantle cell lymphoma.
April 9th 2021
A high intensity immunochemotherapy with maintenance therapy led to 93.2% of patients achieving a complete response and 55.6% of patients with progression-free survival at five years.
April 8th 2021
Researchers found that patients who were never married, had lower educational levels or had comorbidities were less likely to be suggested an autologous hematopoietic cell transplantation, which may underline a need for more informed decision making.
April 6th 2021
Pirtobrutinib was safe and effective in treating patients with chronic lymphocytic leukemia, small lymphocytic lymphoma, mantle cell lymphoma and Waldenstrom macroglobulinemia, some of whom developed intolerance or resistance to previous covalent BTK inhibitors.
March 17th 2021
An interview with Dr. Luhua (Michael) Wang, MD, Department of Lymphoma and Myeloma, Division of Cancer Medicine, MD Anderson Cancer Center
February 16th 2021
A meta-analysis found that minimal residual disease positivity after a particular treatment for mantle cell lymphoma can predict worse survival benefit.
December 29th 2020
A roundup of some of the most read news and updates in mantle cell lymphoma in 2020 from CURE®.
November 16th 2020
This treatment, which included dexamethasone, high-dose cytarabine and cisplatin, was well tolerated in this patient population, although longer-term follow-up is needed to see if the benefit persists.
September 25th 2020
Mantle Cell Lymphoma (MCL), as described in this issue of CURE®, has an interesting and inspiring story. It was one of the first cancers known to have a genetic abnormality-chromosomal translocation t(11;14).
September 22nd 2020
Exciting advances in treatment options for patients with mantle cell lymphoma are greatly improving the outlook for long-term remissions.
September 9th 2020
Dr. Lori A. Leslie discuses the potential of combination therapies with the emerging agent cirmtuzumab for patients with mantle cell lymphoma.
September 2nd 2020
“Moving forward, (bendamustine and Rituxan) will likely become a common backbone for the incorporation of other cytotoxic or novel agents in an attempt to further improve outcomes while maintaining an effective, safe, and ideally outpatient regimen for MCL,” the authors wrote.
August 11th 2020
A roundup of the latest news and updates for patients with mantle cell lymphoma from CURE®.
August 10th 2020
“It really is an exciting time for patients with lymphoma, because the options are just really exploding at a very encouraging rate,” said Dr. Lori A. Leslie.
August 4th 2020
“The FDA approval of (Tecartus) will change the way we treat patients with relapsed MCL forever and for the better,” said Dr. Michael Wang.
August 3rd 2020
The Food and Drug Administration has had a busy summer, approving new agents to treat a variety of cancers. Here are five recent approvals that patients with cancer may have missed.
July 29th 2020
There are some job protected options for patients with cancer, survivors and caregivers to consider when it comes to returning to work during the COVID-19 pandemic. But, as one cancer rights attorney notes, there are many challenges to those options.
July 24th 2020
The FDA’s approval of Tecartus for adults with relapsed or refractory mantle cell lymphoma (MCL) is based on data that showed that the CAR T-cell therapy induced a response in 87% of patients.
July 22nd 2020
Patients with cancer have been encouraged to reach out to legislators and share their personal stories and advocate for why they think continued funding is important to further cancer research.
July 7th 2020
“We learned from previous prospective studies (that) using chemoimmunotherapy for those patients with TP53 aberrations, the survival data compared with others that do not harbor this mutation are much less favorable,” said Dr. Jia Ruan.
July 7th 2020
“It is important to note that the data predates the widespread use of BTK inhibitors and even cellular therapies such as CAR T-cell therapy, specifically,” Dr. Reem Karmali said in an interview. “And so, it doesn't reliably reflect the potential advancements and survival that we've been able to achieve with these novel targeted therapies.”
June 8th 2020
To commemorate National Cancer Survivors Day on June 7, CURE® invited its readers to share their encouraging stories of survival.
May 31st 2020
“Altogether, this pharmacological data supports the concept of CAR T-cell therapy being able to overcome MCL disease with poor risk factors,” said lead study author Dr. Luhua (Michael) Wang.
May 30th 2020
“We now have second and third generation cousins of thalidomide that are very useful. So, lenalidomide in combination with rituximab is an effective therapy for mantle cell lymphoma that voids some of these adverse events that I’m talking about,” said Dr. Ian Flinn. Hear more about this treatment in his interview with CURE®.
May 27th 2020
“I think we’re in a midst of a real shakeup in our treatment paradigms for patients with mantle cell lymphoma, or at least we will be in the next few years,” said Dr. Ian Flinn in an interview with CURE®.
May 26th 2020
The development of bispecific antibodies and antibody drug conjugates could be exciting advancements for patients with lymphomas, including mantle cell lymphoma, according to Dr. Ian Flinn.
May 22nd 2020
Evidence shows that Bruton’s tyrosine kinase inhibitors, one of many targeted therapies, are highly effective in patients with mantle cell lymphoma.
May 21st 2020
The evolution of CAR T-cell therapy has been an exciting development for the treatment of all lymphomas, including mantle cell lymphoma, according to Dr. Ian Flinn.